# South America Drug Repurposing Market > South America Drug Repurposing Market Research Report By Types (Disease-centric, Target-centric, Drug-centric), By Therapeutic Area (Same Therapeutic Area, Different Therapeutic Area), By Drug Molecules (Biologics, Small Molecule) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 15.0% - **2024:** $ 40 Million - **2025:** $ 46 Million - **2035:** $ 186.13 Million - **Key Players:** Pfizer (US), Novartis (CH), Bristol-Myers Squibb (US), Johnson & Johnson (US), AstraZeneca (GB), Roche (CH), Eli Lilly and Company (US), GSK (GB), Sanofi (FR) **Report ID:** MRFR/Pharma/50635-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-america-drug-repurposing-market-52393 --- ## Market Summary ## **South America Drug Repurposing Market Overview** As per MRFR analysis, the South America Drug Repurposing Market Size was estimated at 30 (USD Million) in 2023. The South America Drug Repurposing Market Industry is expected to grow from 33.8(USD Million) in 2024 to 152.1 (USD Million) by 2035. The South America Drug Repurposing Market CAGR (growth rate) is expected to be around 14.652% during the forecast period (2025 - 2035) **Key South America Drug Repurposing Market Trends Highlighted** In South America, the Drug Repurposing Market is experiencing significant shifts driven by several key market drivers. The increasing prevalence of chronic diseases, coupled with the growing demand for cost-effective treatment options, has led to a rising interest in repurposing existing drugs for new therapeutic uses.  Governments in the region are actively promoting research initiatives that facilitate the development of repurposed drugs, providing support to local laboratories and research institutions. This not only accelerates the process of bringing medications to market but also enhances the focus on ethical considerations in drug testing and approval processes. There are substantial opportunities to be explored in the South American market, particularly in addressing unmet medical needs and rare diseases prevalent in the region. The interplay of economic factors and healthcare accessibility is leading organizations to focus on affordable treatments, making repurposing an attractive strategy for pharmaceutical companies. Moreover, collaborations between public and private sectors are fostering an innovative ecosystem, propelling advancements in clinical trial frameworks that support drug repurposing.  Recent trends indicate a growing collaboration between universities and healthcare institutions to leverage academic research for hastening drug repurposing.South America is witnessing an uptick in clinical trials for repurposed drugs, reflecting an increased agility in adapting to emerging health challenges such as infectious diseases and cancer. Also, the integration of digital health solutions is playing a crucial role in tracking patient responses and optimizing treatment plans.  As these developments continue, the South America Drug Repurposing Market is poised for further growth, fostering a proactive healthcare landscape focused on improving patient outcomes efficiently. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South America Drug Repurposing Market Drivers** **Rising Incidence of Chronic Diseases** The increasing prevalence of chronic illnesses, including diabetes, cancer, and cardiovascular disease, is a major factor driving the South America drug repurposing market. The Pan American Health Organization estimates that the number of people with diabetes in the area has increased by 22% in the past five years, reaching an estimated 32 million. An estimated 10 million people in Brazil, for example, have diabetes, which is driving up demand for accessible and efficient treatment options.  Utilizing their current R&D frameworks, pharmaceutical firms may accelerate the availability of therapies to address certain illnesses by repurposing existing medication molecules. To develop solutions for managing chronic conditions in the South American market, well-known companies like Novartis and Roche have made large investments in medication repurposing initiatives, which have fueled market expansion. **Government Initiatives and Framework.** There is a growing trend of supportive government initiatives aimed at promoting drug repurposing efforts in South America. The Brazilian Health Ministry has launched programs to incentivize pharmaceutical companies to engage in drug repurposing research. These initiatives include tax benefits and grants for companies focused on innovative therapeutic solutions derived from existing medications.  Such measures are designed to enhance patient access to therapeutic alternatives while driving overall industry growth.The National Agency for Health Surveillance (ANVISA) has also streamlined the regulatory processes for drug approvals, facilitating an environment ripe for new therapeutic interventions aimed at addressing the needs of the population, thus positively impacting the South America Drug Repurposing Market Industry. **Technological Advancements in Drug Discovery.** Advancements in technology and computational biology have revolutionized the process of drug repurposing, making it more efficient and cost-effective. Machine learning and artificial intelligence applications are aiding researchers and pharmaceutical companies in identifying potential repurposing candidates with greater accuracy. For example, Mexico's National Autonomous University has reported that integrating AI in drug discovery can reduce the average time to identify repurposed drugs by as much as 30%. This enables faster delivery of treatments to patients while utilizing existing compounds more effectively, thereby stimulating growth in the South America Drug Repurposing Market Industry as companies strive to remain competitive in an evolving landscape. **South America Drug Repurposing Market Segment Insights** **Drug Repurposing Market Types Insights** The South America Drug Repurposing Market showcases a comprehensive segmentation centered around Types, with major areas including Disease-centric, Target-centric, and Drug-centric approaches. This market is driven by the need for innovative solutions to existing health challenges, and the Drug Repurposing strategy presents a promising avenue to expedite the availability of therapies. The Disease-centric aspect captures attention as it focuses on specific illnesses and combating them through existing drugs, which not only reduces Research and Development costs but also greatly shortens the timelines required for bringing treatments to patients. Target-centric approaches emphasize the importance of particular biological targets for therapy, making them crucial in optimizing drug efficacy and minimizing side effects, thereby significantly enhancing patient outcomes. The Drug-centric focus presents a unique opportunity to extend the therapeutic use of established drugs, offering cost-effective alternatives that can rejuvenate drug pipelines and reduce the burden on healthcare systems. In the South America region, where healthcare disparities exist, innovative drug repurposing strategies could transform the landscape by improving access to treatments in a timelier fashion. The market dynamics reflect growing recognition of these methodologies, with various stakeholders acknowledging the significance of leveraging existing drugs to tailor treatments for diverse populations. Moreover, as the South America Drug Repurposing Market data indicates, the rise in chronic diseases and increasing prevalence of complex medical conditions amplify the relevance of these types. The statistics suggest that the ongoing emphasis on cost-effective solutions is likely to promote advancements in these areas, encouraging collaborations between healthcare entities, academic institutions, and regulatory bodies. This aligns with regional healthcare policies focused on improving patient accessibility and outcomes, thus creating a robust environment for growth rooted in innovative yet practical approaches to drug use. Overall, the Types segmentation in the South America Drug Repurposing Market hints at significant potential and opportunities that can reshape therapeutic strategies in the region. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Drug Repurposing Market Therapeutic Area Insights** The Therapeutic Area segment of the South America Drug Repurposing Market is gaining traction as an essential component of pharmaceutical development within the region. This segment includes repurposing drugs within the same therapeutic area as well as exploring entirely different therapeutic categories. The focus on the Same Therapeutic Area often leads to a quicker return on investment due to existing knowledge of the drug's safety profile and pharmacodynamics.  Conversely, repurposing into Different Therapeutic Areas offers vast potential for untapped therapies and could address unmet medical needs, especially in a diverse healthcare landscape like South America, where diseases can vary significantly between urban and rural populations.The region's unique disease burdens, such as tropical diseases and chronic conditions, highlight the necessity for innovative approaches in treatment options, fostering an environment conducive to drug repurposing initiatives.  Expansion in clinical research and collaborations between academic institutions and pharmaceutical companies are also contributing to the growth of this segment, allowing for the identification of novel uses for existing drugs, thus aligning with emerging healthcare needs and improving patient outcomes in South America. Overall, understanding the Therapeutic Area dynamics offers valuable insights into how the South America Drug Repurposing Market is evolving and adapting to regional healthcare challenges. **Drug Repurposing Market Drug Molecules Insights** The South America Drug Repurposing Market exhibits a strong focus on Drug Molecules, which include pivotal categories such as Biologics and Small Molecules. The growing demand for innovative treatment solutions in South America has propelled the significance of Drug Molecules, as they offer opportunities for expedited development and lower costs. Biologics have become increasingly important due to their efficacy in treating chronic diseases and their ability to target specific pathways, providing clinicians with advanced options.  Meanwhile, Small Molecules are essential for their versatility and established delivery mechanisms, making them indispensable in therapeutic regimens across various disease states.As the South American population continues to experience rising healthcare needs, the demand for Drug Molecules is expected to expand, offering both challenges and opportunities for pharmaceutical companies operating in the region.  The focus on Drug Molecules aligns with ongoing advancements in biotechnology and Research and Development efforts, further highlighting the dynamic nature of the South America Drug Repurposing Market. **South America Drug Repurposing Market Key Players and Competitive Insights** The South America Drug Repurposing Market has been gaining traction due to various factors such as the increasing prevalence of chronic diseases, the rising costs associated with drug development, and the growing demand for cost-effective treatment options. Drug repurposing, the strategy of finding new uses for existing medications, allows for quicker regulatory approval and market entry compared to traditional drug development.  The landscape of this market is characterized by a plethora of players, including pharmaceutical giants, biotech firms, and research institutions. These stakeholders are continuously vying for a competitive edge by enhancing their research capabilities, expanding their operational footprints, and engaging in strategic collaborations.  Emerging economies in South America, undergoing rapid healthcare advancements and investments, further contribute to the dynamic nature of this market, making it essential for companies to adopt innovative approaches and leverage local partnerships.AstraZeneca has established a notable presence in the South America Drug Repurposing Market with its strong commitment to research and development, particularly focusing on diseases with significant unmet medical needs. The company has a vast portfolio that includes a range of therapeutic areas such as oncology, cardiovascular, and respiratory diseases.  AstraZeneca's strengths lie in its robust pipeline of repurposed drugs, supported by extensive clinical research and collaborations with local healthcare institutions. Their experience in navigating regulatory pathways in various South American countries enhances their ability to bring repurposed drugs to market efficiently. This strategic positioning allows AstraZeneca to capitalize on its existing infrastructure and resources while addressing local health challenges through tailored repurposing strategies.Roche has made significant strides in the South America Drug Repurposing Market with its focus on innovative therapies and personalized medicine.  The company is well-regarded for its cutting-edge research and development initiatives, particularly in oncology and rare diseases, which play a crucial role in drug repurposing efforts. Roche's strengths include a solid portfolio of products that have shown potential for repurposing, in addition to its commitment to advancing scientific research through partnerships with regional healthcare providers and academic institutions. The company has also engaged in several strategic mergers and acquisitions aimed at bolstering its capabilities in drug discovery and development, allowing it to enhance its market share in South America.  Roche's collaborative approach, coupled with its extensive experience in navigating the complexities of the South American healthcare regulatory landscape, positions it as a formidable player in this evolving market. **Key Companies in the South America Drug Repurposing Market Include** **South America Drug Repurposing Market Industry Developments** Recent developments in the South America Drug Repurposing Market are notable, particularly with companies like AstraZeneca, Roche, and Merck and Co., which have accelerated their efforts in innovative drug reuse strategies amid growing public health challenges. The pandemic has led to enhanced collaboration among pharmaceutical firms, including a surge in partnerships between Eli Lilly and Sanofi for joint initiatives focusing on repurposed therapies in treating infectious diseases prevalent in the region.  In August 2023, AstraZeneca announced its plans to invest in strengthening its Research and Development capabilities, specifically targeting diseases endemic to South America. Additionally, there was a reported acquisition of a smaller biotech firm by Roche in September 2023, aimed at enhancing their portfolio in rare disease treatments that could benefit from repurposing existing drugs. Over the last two to three years, significant market growth is observed, especially with Novartis and Pfizer working on developing treatment protocols for conditions like COVID-19 and its long-term effects, significantly impacting local healthcare systems. This growth underscores the increasing importance of drug repurposing in addressing unmet medical needs across South America. **South America Drug Repurposing Market Segmentation Insights** ## Market Drivers ### Rising Healthcare Costs The escalating costs associated with healthcare in South America are driving interest in the drug repurposing market. As healthcare expenditures continue to rise, stakeholders are increasingly seeking cost-effective solutions to address various medical conditions. Drug repurposing offers a viable pathway to reduce development costs, as existing drugs can be utilized for new therapeutic indications. This approach not only shortens the time to market but also minimizes the financial burden on healthcare systems. In South America, where healthcare budgets are often constrained, the potential for repurposed drugs to provide affordable treatment options is particularly appealing. The drug repurposing market is thus positioned to benefit from this trend, as it aligns with the need for innovative yet economical healthcare solutions. ### Advancements in Technology Technological advancements are playing a pivotal role in shaping the drug repurposing market in South America. Innovations in data analytics, artificial intelligence, and bioinformatics are enhancing the ability to identify new therapeutic uses for existing drugs. These technologies facilitate the analysis of vast datasets, enabling researchers to uncover potential repurposing opportunities more efficiently. As a result, the drug repurposing market is experiencing a surge in interest from both public and private sectors. The integration of technology not only accelerates the research process but also improves the accuracy of predictions regarding drug efficacy for new indications, thereby fostering a more robust pipeline of repurposed drugs. ### Regulatory Framework Enhancements The evolving regulatory landscape in South America is positively impacting the drug repurposing market. Regulatory bodies are increasingly recognizing the value of repurposed drugs in expediting access to treatments. Streamlined approval processes and supportive policies are being implemented to facilitate the development and commercialization of repurposed medications. This regulatory support is crucial for the drug repurposing market, as it reduces barriers to entry and encourages investment in this area. By fostering a more favorable regulatory environment, authorities are likely to stimulate innovation and enhance the availability of effective therapies for patients in need. ### Growing Burden of Non-Communicable Diseases The rising prevalence of non-communicable diseases (NCDs) in South America is significantly influencing the drug repurposing market. Conditions such as diabetes, cardiovascular diseases, and cancer are becoming increasingly common, necessitating the development of effective treatment strategies. Drug repurposing presents an opportunity to quickly provide therapies for these diseases by leveraging existing medications. The World Health Organization has indicated that NCDs account for approximately 70% of all deaths in the region, underscoring the urgent need for innovative solutions. The drug repurposing market is likely to thrive as it addresses this growing health crisis, offering a faster and more cost-effective means to combat the rising tide of NCDs. ### Increased Investment in Research and Development Investment in research and development (R&D) is crucial for the growth of the drug repurposing market in South America. Governments and private entities are recognizing the potential of repurposed drugs to address unmet medical needs. As a result, funding for R&D initiatives is on the rise, with a focus on exploring new applications for existing medications. This influx of capital is likely to enhance the capabilities of research institutions and pharmaceutical companies, leading to a more dynamic drug repurposing market. The commitment to R&D not only fosters innovation but also encourages collaboration among stakeholders, further propelling the market forward. ## Future Outlook The [Drug Repurposing Market](https://www.marketresearchfuture.com/reports/drug-repurposing-market-22086) is projected to grow at a 15.0% CAGR from 2025 to 2035, driven by increasing R&D investments and regulatory support. **New opportunities:** - Development of AI-driven drug screening platforms - Partnerships with biotech firms for clinical trials - Expansion of telehealth services for patient monitoring By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Disease-centric (Largest) vs. Target-centric (Fastest-Growing) In the South America drug repurposing market, the Disease-centric approach holds the largest share, dominating the strategies employed in this sector. This strategy revolves around identifying drugs that can potentially treat various diseases, leveraging existing knowledge about their safety and efficacy. Target-centric strategies, while currently smaller in market share, are gaining traction as they focus on specific biological targets, offering specialized treatment options in a rapidly evolving landscape. Growth trends indicate that the Target-centric approach is emerging as the fastest-growing segment within the market, driven by advancements in biotechnology and precision medicine. Both approaches are influenced by increasing investment in research and development, coupled with a push towards personalized medicine. The shift in focus towards precision therapy provides robust opportunities for growth and innovation in the repurposing of drugs. Disease-centric (Dominant) vs. Target-centric (Emerging) The Disease-centric approach has established itself as the dominant force in the South America drug repurposing market due to its comprehensive focus on leveraging existing drugs to treat a wide range of diseases. This strategy capitalizes on the extensive data available for established medications, minimizing the risks associated with new drug development. On the other hand, the Target-centric approach is emerging as a critical player as it seeks to identify specific biological markers and targets for treatment. This method allows for tailored therapies and potentially higher response rates in patients, appealing to stakeholders interested in innovative healthcare solutions. Both strategies play significant roles, but their applications and implications for patient care differ markedly. ### By Therapeutic Area: Same Therapeutic Area (Largest) vs. Different Therapeutic Area (Fastest-Growing) In the therapeutic area segment, Same Therapeutic Area dominates the landscape, holding a substantial market share due to its established protocols and familiarity among healthcare providers. This segment benefits from existing drug formulations that are being repurposed to treat indications within the same therapeutic domain, ensuring a lower development risk and faster regulatory approvals. Conversely, Different Therapeutic Area is making significant inroads, rapidly expanding as innovative research unveils potential in repurposing existing drugs for entirely new conditions, thereby driving market growth. Growth trends indicate a robust increase in the adoption of repurposed drugs across both segments. The Same Therapeutic Area continues to thrive as pharmaceutical companies leverage previously successful drugs for new applications, propelled by the need for cost-effective solutions. Meanwhile, the Different Therapeutic Area segment is gaining momentum, propelled by advancements in biotechnology and a growing emphasis on personalized medicine. As scientific understanding deepens, the potential for repurposing drugs for different therapeutic areas is becoming increasingly viable, fostering a competitive environment for market players. Same Therapeutic Area (Dominant) vs. Different Therapeutic Area (Emerging) The Same Therapeutic Area segment remains a dominant force in the drug repurposing market, characterized by its strong reliance on existing medications to meet emerging patient needs. This segment benefits from lower risk profiles, as the efficacy and safety of these drugs are often well-established. Healthcare professionals are more inclined to utilize repurposed drugs within the same therapeutic area, ensuring quicker acceptance and integration into treatment protocols. On the other hand, the Different Therapeutic Area segment represents an emerging opportunity, showcasing innovation and the potential for lucrative outcomes as drugs are explored for new uses. Driven by groundbreaking research and an increasing number of clinical trials, this segment is poised for rapid growth, with potential applications spanning various conditions, thus attracting significant investment and attention from pharmaceutical companies. ### By Drug Molecules: Biologics (Largest) vs. Small Molecule (Fastest-Growing) In the South America drug repurposing market, the distribution of market share reveals that Biologics hold the largest segment, dominating due to their wide applicability in treating complex diseases. Small Molecule substances, while smaller in share, are rapidly gaining traction owing to their ease of manufacturing and development, making them an attractive alternative for many drug developers. The diversification in therapeutic areas plays a significant role in this distribution. The growth trends in this market are driven by the increasing interest in Biologics, particularly in the realm of monoclonal antibodies and targeted therapies that address specific ailments. Conversely, the Small Molecule segment is experiencing rapid growth due to advancements in technology that streamline the drug repurposing process. This includes enhanced computational methods for drug screening and the expanding pipeline of generic drugs that provide cost-effective treatment options, appealing to both healthcare providers and patients alike. Biologics (Dominant) vs. Small Molecule (Emerging) Biologics are currently positioned as the dominant force in the drug repurposing landscape, leveraging their ability to target specific pathways and produce significant therapeutic effects. They are characterized by their complex structures, which require intricate manufacturing processes, giving them a competitive edge in treating challenging health conditions. On the other hand, Small Molecule drugs are emerging as a vital segment with a growing presence. They are simpler in structure and can be administered orally, leading to vast potential in therapeutic applications across various indications. The increase in research initiatives and funding for both segments signifies the evolving landscape, showcasing the dynamic interplay between these two drug categories. ## Regional Market Share Analysis ### Brazil : Strong Growth Driven by Innovation Brazil holds the largest market share in South America at 18.0%, reflecting a robust drug repurposing sector valued at approximately $1.5 billion. Key growth drivers include increasing healthcare expenditure, a rising prevalence of chronic diseases, and supportive government initiatives aimed at fostering pharmaceutical innovation. Regulatory policies are becoming more favorable, with streamlined approval processes for repurposed drugs, enhancing market accessibility. Additionally, Brazil's well-established healthcare infrastructure supports extensive clinical trials and research activities. ### Mexico : Growing Demand and Investment Opportunities Mexico commands a 10.0% market share in the South American drug repurposing landscape, valued at around $800 million. The market is driven by increasing investments in healthcare and a growing demand for affordable treatment options. The government has initiated several programs to support pharmaceutical research, including tax incentives for companies involved in drug repurposing. The consumption pattern is shifting towards more innovative therapies, reflecting a broader acceptance of repurposed drugs in clinical settings. ### Argentina : Focus on Localized Healthcare Solutions With a 7.0% market share, Argentina's drug repurposing market is valued at approximately $600 million. The growth is fueled by a rising incidence of diseases and a push for localized healthcare solutions. Government policies are increasingly supportive, with initiatives aimed at enhancing research capabilities and funding for clinical trials. The demand for repurposed drugs is growing, particularly in urban areas where healthcare access is improving, driven by public health campaigns and awareness. ### Rest of South America : Untapped Markets Awaiting Exploration The Rest of South America holds a 5.0% market share in the drug repurposing sector, valued at about $400 million. This sub-region presents diverse opportunities, driven by varying healthcare needs and regulatory environments. Countries like Chile and Colombia are emerging as potential markets due to their improving healthcare systems and increasing investment in pharmaceutical research. The competitive landscape is fragmented, with local players gaining traction alongside multinational corporations, creating a dynamic business environment. ## Competitive Benchmarking The drug repurposing market in South America is characterized by a dynamic competitive landscape, driven by the increasing need for cost-effective therapeutic solutions and the rising prevalence of chronic diseases. Major players such as Pfizer (US), Novartis (CH), and AstraZeneca (GB) are strategically positioned to leverage their extensive research capabilities and established market presence. These companies are focusing on innovation and partnerships to enhance their drug repurposing initiatives, thereby shaping a competitive environment that emphasizes collaboration and technological advancement.Key business tactics employed by these companies include localizing manufacturing and optimizing supply chains to improve efficiency and reduce costs. The market appears moderately fragmented, with a mix of large multinational corporations and smaller biotech firms. The collective influence of these key players is significant, as they not only drive innovation but also set industry standards that smaller entities often follow. In October Pfizer (US) announced a collaboration with a local biotech firm to explore the repurposing of existing therapies for rare diseases prevalent in South America. This strategic move is likely to enhance Pfizer's portfolio while addressing unmet medical needs in the region, thereby reinforcing its commitment to localized healthcare solutions. Such partnerships may also facilitate faster regulatory approvals and market access. In September Novartis (CH) launched a new initiative aimed at repurposing its existing oncology drugs for use in treating autoimmune disorders. This initiative underscores Novartis's focus on leveraging its existing drug library to discover new therapeutic applications, potentially reducing development timelines and costs. The strategic importance of this move lies in its ability to diversify Novartis's product offerings while addressing significant health challenges in the region. In August AstraZeneca (GB) expanded its research collaboration with academic institutions in Brazil to investigate the repurposing of its cardiovascular drugs for neurological conditions. This strategic action highlights AstraZeneca's commitment to innovation through academic partnerships, which may lead to groundbreaking discoveries and enhance its competitive edge in the market. The collaboration is expected to yield valuable insights that could inform future drug development strategies. As of November current trends in the drug repurposing market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in research and development processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaborative efforts in accelerating drug discovery and enhancing patient outcomes. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, positioning companies to better meet the complex demands of the healthcare landscape. ## Recent News & Developments Recent developments in the South America Drug Repurposing Market are notable, particularly with companies like AstraZeneca, Roche, and Merck and Co., which have accelerated their efforts in innovative drug reuse strategies amid growing public health challenges. The pandemic has led to enhanced collaboration among pharmaceutical firms, including a surge in partnerships between Eli Lilly and Sanofi for joint initiatives focusing on repurposed therapies in treating infectious diseases prevalent in the region.  In August 2023, AstraZeneca announced its plans to invest in strengthening its Research and Development capabilities, specifically targeting diseases endemic to South America. Additionally, there was a reported acquisition of a smaller biotech firm by Roche in September 2023, aimed at enhancing their portfolio in rare disease treatments that could benefit from repurposing existing drugs. Over the last two to three years, significant market growth is observed, especially with Novartis and Pfizer working on developing treatment protocols for conditions like COVID-19 and its long-term effects, significantly impacting local healthcare systems. This growth underscores the increasing importance of drug repurposing in addressing unmet medical needs across South America. ## Report Scope | MARKET SIZE 2024 | 40.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 46.0(USD Million) | | MARKET SIZE 2035 | 186.13(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 15.0% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Pfizer (US), Novartis (CH), Bristol-Myers Squibb (US), Johnson & Johnson (US), AstraZeneca (GB), Roche (CH), Eli Lilly and Company (US), GSK (GB), Sanofi (FR) | | Segments Covered | Type, Therapeutic Area, Drug Molecules | | Key Market Opportunities | Emerging technologies enhance efficiency in drug repurposing, addressing unmet medical needs and regulatory challenges. | | Key Market Dynamics | Growing interest in drug repurposing driven by regulatory support and technological advancements in South America. | | Countries Covered | Brazil, Mexico, Argentina, Rest of South America | ## Frequently Asked Questions **Q: What was the market valuation of the drug repurposing market in 2024?** A: The market valuation was $40.0 Million in 2024. **Q: What is the projected market valuation for 2035?** A: The projected market valuation for 2035 is $186.13 Million. **Q: What is the expected CAGR for the drug repurposing market during 2025 - 2035?** A: The expected CAGR for the market during 2025 - 2035 is 15.0%. **Q: Which companies are the key players in the drug repurposing market?** A: Key players include Pfizer, Novartis, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, Roche, Eli Lilly and Company, GSK, and Sanofi. **Q: What are the main segments of the drug repurposing market?** A: The main segments include Type, Therapeutic Area, and Drug Molecules. **Q: What was the valuation for the 'Drug-centric' segment in 2024?** A: The valuation for the 'Drug-centric' segment was $15.0 Million in 2024. **Q: How does the valuation of 'Small Molecule' compare to 'Biologics' in 2024?** A: In 2024, 'Small Molecule' had a valuation of $30.0 Million, significantly higher than 'Biologics' at $10.0 Million. **Q: What is the valuation range for the 'Different Therapeutic Area' segment?** A: The valuation range for the 'Different Therapeutic Area' segment is $20.0 Million to $96.13 Million. **Q: What is the projected growth for the 'Target-centric' segment by 2035?** A: The 'Target-centric' segment is projected to grow from $15.0 Million to $69.0 Million by 2035. **Q: What does the market data suggest about the future of drug repurposing in South America?** A: The data suggests a robust growth trajectory, with a projected valuation increase to $186.13 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-drug-repurposing-market-52393*